A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors

Stephen K-F Wong1

  • 1Department of Neuroscience, Pfizer Global Research Development, Pfizer Inc., Easter Point Road, Groton, CT 06340, USA. stephen_wong@groton.pfizer.com

Analytical Biochemistry
|September 29, 2004
PubMed

Insights

A new, high-throughput assay quantifies extracellular signal-regulated kinase (ERK) phosphorylation, enabling precise monitoring of dopamine receptor pharmacology and other signaling pathways.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Extracellular signal-regulated kinase (ERK) phosphorylation is a key indicator of cell surface receptor and kinase activation.
  • Existing methods for detecting phospho-ERK lack the quantification and throughput needed for robust pharmacological studies.

Purpose of the Study:

  • To develop a high-throughput, quantitative assay for measuring dopamine agonist-induced ERK phosphorylation.
  • To validate the assay's utility for determining pharmacological parameters of D2 and D3 receptor ligands.

Main Methods:

  • A 384-well, cell-based functional assay utilizing infrared-labeled secondary antibodies to detect phospho-ERK.
  • Quantification of signals using a LI-COR infrared scanner in D2- and D3-overexpressed cell lines.

Main Results:

  • The assay accurately determined V(max), EC(50), and functional K(i) values for D2 and D3 agonists and antagonists, consistent with literature values.
  • The assay demonstrated to be nonradioactive, quantitative, stable, and possess a good signal-to-noise ratio.

Conclusions:

  • This novel assay provides a reliable and efficient method for monitoring ERK phosphorylation.
  • The methodology is applicable to studying a wide range of G protein-coupled receptors and other signaling biomolecules linked to ERK phosphorylation.
  • The technique has potential for detecting changes in any cellular protein using selective antibodies.

Related Concept Videos